117 related articles for article (PubMed ID: 38165019)
1. Individualized rabbit anti-thymocyte globulin dosing in adult haploidentical hematopoietic cell transplantation with high-risk hematologic malignancy: Exposure-response analysis and population pharmacokinetics simulations.
Teramoto M; Takahashi T; Matsumoto K; Jaber M; Kaida K; Tamaki H; Ikegame K; Yoshihara S
Am J Hematol; 2024 Mar; 99(3):387-395. PubMed ID: 38165019
[TBL] [Abstract][Full Text] [Related]
2. Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell-depleted hematopoietic cell transplantation in pediatric and young adult patients.
Lakkaraja M; Mauguen A; Boulad F; Cancio MI; Curran KJ; Harris AC; Kernan NA; Klein E; Kung AL; Oved J; Prockop S; Scaradavou A; Spitzer B; O'Reilly RJ; Boelens JJ
Cytotherapy; 2024 Apr; 26(4):351-359. PubMed ID: 38349310
[TBL] [Abstract][Full Text] [Related]
3. Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation.
Lakkaraja M; Scordo M; Mauguen A; Cho C; Devlin S; Ruiz JD; Klein E; Avecilla ST; Boulad F; Cancio MI; Curran KJ; Jakubowski AA; Kernan NA; Kung AL; O'Reilly RJ; Papadopoulos EB; Prockop S; van Roessel I; Scaradavou A; Shaffer BC; Shah G; Spitzer B; Tamari R; Giralt SA; Perales MA; Boelens JJ
Blood Adv; 2022 Feb; 6(3):1054-1063. PubMed ID: 34788361
[TBL] [Abstract][Full Text] [Related]
4. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of TBI+rATG-based conditioning regimen for haploidentical allogeneic hematopoietic stem cell transplantation in 11 cases of chemotherapy-resistant advanced peripheral T-cell lymphoma].
Xu R; Li S; Liu HX; Wei DL; Jiang Y; Wang JJ; Liu SS; Wang C; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):578-581. PubMed ID: 37749039
[No Abstract] [Full Text] [Related]
6. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Total Rabbit Anti-thymocyte Globulin in Non-obese Adult Patients Undergoing Hematopoietic Cell Transplantation for Hematologic Malignancy.
Takahashi T; Teramoto M; Matsumoto K; Jaber MM; Tamaki H; Ikegame K; Yoshihara S; Kaida K
Clin Pharmacokinet; 2023 Aug; 62(8):1081-1091. PubMed ID: 37284975
[TBL] [Abstract][Full Text] [Related]
8. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.
Admiraal R; van Kesteren C; Jol-van der Zijde CM; Lankester AC; Bierings MB; Egberts TC; van Tol MJ; Knibbe CA; Bredius RG; Boelens JJ
Lancet Haematol; 2015 May; 2(5):e194-203. PubMed ID: 26688094
[TBL] [Abstract][Full Text] [Related]
9. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis.
Admiraal R; Nierkens S; de Witte MA; Petersen EJ; Fleurke GJ; Verrest L; Belitser SV; Bredius RGM; Raymakers RAP; Knibbe CAJ; Minnema MC; van Kesteren C; Kuball J; Boelens JJ
Lancet Haematol; 2017 Apr; 4(4):e183-e191. PubMed ID: 28330607
[TBL] [Abstract][Full Text] [Related]
10. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy analysis of anti-thymocyte globulin regimens with different timing strategies for matched sibling donor hematopoietic stem cell transplantation].
Du JS; Wang HT; Dou LP; Wang N; Li F; Jin XS; Liu DH
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):660-666. PubMed ID: 37803840
[No Abstract] [Full Text] [Related]
12. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation.
Penack O; Abouqateb M; Peczynski C; Boreland W; Gülbas Z; Gedde-Dahl T; Castilla-Llorente C; Kröger N; Eder M; Rambaldi A; Bonifazi F; Blau IW; Stelljes M; Dreger P; Moiseev I; Schoemans H; Koenecke C; Peric Z
Blood Cancer J; 2024 Mar; 14(1):45. PubMed ID: 38485723
[TBL] [Abstract][Full Text] [Related]
13. Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation.
Tian Z; Man Q; Yang Y; Guan H; Wang Y; Luo R; Wang J
Ann Hematol; 2024 May; 103(5):1729-1736. PubMed ID: 38538977
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Elmariah H; Otoukesh S; Kumar A; Ali H; Arslan S; Shouse G; Pourhassan H; Nishihori T; Faramand R; Mishra A; Khimani F; Fernandez H; Lazaryan A; Nieder M; Perez L; Liu H; Nakamura R; Pidala J; Marcucci G; Forman SJ; Anasetti C; Locke F; Bejanyan N; Al Malki MM
Transplant Cell Ther; 2024 Feb; 30(2):229.e1-229.e11. PubMed ID: 37952648
[TBL] [Abstract][Full Text] [Related]
15. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
16. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.
Stocker N; Duléry R; Battipaglia G; Brissot E; Médiavilla C; Sestili S; Paviglianiti A; Ledraa T; Mohty R; Bazarbachi A; Belhocine R; Vekhoff A; Ruggeri A; Mohty M; Malard F
Eur J Haematol; 2019 Jul; 103(1):10-17. PubMed ID: 30958904
[TBL] [Abstract][Full Text] [Related]
17. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
18. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors.
Wang N; Wang H; Fang S; Du J; Huang S; Li F; Jin X; Jia M; Xu L; Dou L; Liu D
Transplant Cell Ther; 2022 Nov; 28(11):769.e1-769.e9. PubMed ID: 35973670
[TBL] [Abstract][Full Text] [Related]
19. [Clinical research of HLA-haploidentical peripheral hematopoietic stem cell transplantation following reduced intensity conditioning regimen with hematological malignancy patients over 50 years old].
Liu Y; Yuan HL; Duan XL; Xu JL; Qu JH; Chen G; Shi J; Han CX; Ding LL; Jiang M
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):667-672. PubMed ID: 31495134
[No Abstract] [Full Text] [Related]
20. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
